Literature DB >> 8640163

Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.

C S Rosenfeld1, B Bolwell, A LeFever, R Taylor, A List, J Fay, R Collins, F Andrews, P Pallansch, M W Schuster, D Resta, D Levitt, J Nemunaitis.   

Abstract

Improved methods for mobilization may reduce the number of aphereses required to collect adequate numbers of peripheral blood stem cells (PBSC) and hasten engraftment following high-dose therapy. Mobilization with cytokines alone enables engraftment after myeloablative therapy. The optimal cytokine regimen for mobilization has not been established. The study evaluated the effects of four interleukin-3-containing cytokine regimens administered during steady state hematopoiesis on PBSC mobilization in 30 patients with breast cancer or lymphoid malignancies. These regimens included IL-3 alone (Arm 1), sequential IL-3 --> G-GSF (Arm 2), sequential IL-3 --> GM-CSF (Arm 3) and combined IL-3 + G-CSF (Arm 4). Consecutive days of apheresis were performed until a target of 4-6 x 10(8) mononuclear cells/kg were collected. All patients received intravenous GM-CSF after PBSC infusion. Median days to an ANC > or = 500/ microliters in Arm 3(22 days) was significantly slower than for patients in Arm 2 (13 days) but not significantly different from patients in Arm 1 or Arm 4. There was no significant difference in platelet engraftment or days of hospitalization between the study arms. Addition of GM-CSF to IL-3-containing mobilization regimens results in collection of PBSC that lead to delayed engraftment. Further development of Arms 1, 2, and 4 appear warranted.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640163

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

Review 1.  Targeting stem cell niches and trafficking for cardiovascular therapy.

Authors:  Nicolle Kränkel; Gaia Spinetti; Silvia Amadesi; Paolo Madeddu
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

2.  High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels.

Authors:  E J Kanfer; D McGuigan; D Samson; Z Abboudi; G Abrahamson; J F Apperley; S Chilcott; C Craddock; J Davis; C MacDonald; D Macdonald; E Olavarria; N Philpott; G J Rustin; M J Seckl; M Sekhar; S Stern; E S Newlands
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.